-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Blueprint Medicines, Raises Price Target to $129

Benzinga·06/05/2025 12:51:21
Listen to the news
UBS analyst David Dai maintains Blueprint Medicines (NASDAQ:BPMC) with a Neutral and raises the price target from $88 to $129.